SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD. Financials Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Equities
002399
CNE100000P02
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.03 CNY | +6.47% |
|
+19.63% | -5.97% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 24,333 | 23,671 | 22,787 | 17,090 | 15,345 | 13,624 | - | - |
| Enterprise Value (EV) 1 | 24,333 | 26,552 | 25,393 | 21,304 | 19,142 | 13,557 | 17,656 | 13,273 |
| P/E ratio | 23 x | 22.8 x | 104 x | 25.9 x | -22 x | 23.5 x | 20.7 x | 19.2 x |
| Yield | 0.92% | 0.87% | 0.2% | 0.78% | - | 0.48% | 0.58% | 0.58% |
| Capitalization / Revenue | 5.26 x | 4.44 x | 3.58 x | 2.39 x | 2.82 x | 2.34 x | 2.14 x | 2 x |
| EV / Revenue | 5.26 x | 4.98 x | 3.99 x | 2.98 x | 3.52 x | 2.33 x | 2.77 x | 1.95 x |
| EV / EBITDA | - | 16.5 x | 50.6 x | 15.4 x | -37.6 x | 13.8 x | 15.6 x | 10.5 x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Price to Book | 3.31 x | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 1,247,202 | 1,467,296 | 1,467,296 | 1,467,296 | 1,467,296 | 1,467,296 | - | - |
| Reference price 2 | 19.51 | 17.22 | 17.10 | 12.85 | 11.73 | 10.36 | 10.36 | 10.36 |
| Announcement Date | 2/28/20 | 3/29/21 | 3/30/22 | 3/29/23 | 3/28/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 4,625 | 5,332 | 6,365 | 7,159 | 5,446 | 5,816 | 6,365 | 6,796 |
| EBITDA 1 | - | 1,607 | 502 | 1,387 | -509.6 | 982 | 1,133 | 1,260 |
| EBIT 1 | 1,315 | 1,330 | 926.4 | 828.6 | -860.9 | 752.3 | 895.5 | 1,013 |
| Operating Margin | 28.43% | 24.94% | 14.55% | 11.57% | -15.81% | 12.94% | 14.07% | 14.91% |
| Earnings before Tax (EBT) 1 | 1,315 | 1,328 | 222.3 | 829.9 | -928.3 | 570.2 | 751.1 | 925.5 |
| Net income 1 | 1,059 | 1,024 | 240.8 | 727.1 | -783.3 | 473.2 | 623.4 | 768.1 |
| Net margin | 22.91% | 19.21% | 3.78% | 10.16% | -14.38% | 8.14% | 9.79% | 11.3% |
| EPS 2 | 0.8494 | 0.7568 | 0.1641 | 0.4955 | -0.5338 | 0.4400 | 0.5000 | 0.5400 |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | 0.1800 | 0.1500 | 0.0350 | 0.1000 | - | 0.0500 | 0.0600 | 0.0600 |
| Announcement Date | 2/28/20 | 3/29/21 | 3/30/22 | 3/29/23 | 3/28/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,791 | 1,910 | 1,846 | 1,637 | 1,756 | 1,301 | 1,405 | 1,350 | 1,368 | 1,387 | 1,407 | 1,531 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | 164.8 | 283.5 | - | 212 | 233.6 | 73.65 | - | - | - | 104.5 | 201.9 | 179.2 |
| Operating Margin | 9.2% | 14.84% | - | 12.95% | 13.3% | 5.66% | - | - | - | 7.54% | 14.35% | 11.7% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - | - |
| Net income | - | - | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/30/22 | 4/29/22 | 8/29/22 | 10/28/22 | 3/29/23 | 4/28/23 | 8/30/23 | 10/30/23 | 3/28/24 | - | - | - |
1CNY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | 2,881 | 2,606 | 4,214 | 3,797 | - | 4,031 | - |
| Net Cash position 1 | - | - | - | - | - | 67.8 | - | 351 |
| Leverage (Debt/EBITDA) | - | 1.793 x | 5.191 x | 3.037 x | -7.451 x | - | 3.558 x | - |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | 15.8% | 11.2% | 2.09% | 6.12% | -6.6% | 5.33% | 5.79% | 5.86% |
| ROA (Net income/ Total Assets) | - | - | - | 3.13% | - | - | - | - |
| Assets 1 | - | - | - | 23,255 | - | - | - | - |
| Book Value Per Share | 5.890 | - | - | - | - | - | - | - |
| Cash Flow per Share | -0.1800 | - | - | - | - | - | - | - |
| Capex | 362 | - | - | 222 | - | - | - | - |
| Capex / Sales | 7.83% | - | - | 3.11% | - | - | - | - |
| Announcement Date | 2/28/20 | 3/29/21 | 3/30/22 | 3/29/23 | 3/28/24 | - | - | - |
1CNY in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
SELL
Number of Analysts
1
Last Close Price
10.36
CNY
Average target price
6.4
CNY
Spread / Average Target
-38.22%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -11.68% | 1.88B | |
| +21.41% | 43.48B | |
| +20.67% | 22.65B | |
| +14.04% | 14.73B | |
| +14.21% | 13.79B | |
| +48.11% | 12.04B | |
| -8.37% | 7.08B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +11.90% | 5.47B |
- Stock Market
- Equities
- 002399 Stock
- Financials Shenzhen Hepalink Pharmaceutical Group Co., Ltd.